Metformin during Pregnancy: Effects on Offspring Development and Metabolic Function

Vista sencilla de ítem
dc.contributor.authorJorquera, Gonzalo
dc.contributor.authorEchiburu, Bárbara
dc.contributor.authorCrisosto, Nicolás
dc.contributor.authorSotomayor-Zárate, Ramón
dc.contributor.authorMaliqueo, Manuel
dc.contributor.authorCruz, Gonzalo
dc.date.accessioned2022-03-08T19:50:46Z
dc.date.available2022-03-08T19:50:46Z
dc.date.issued2020-06-17
dc.description.abstractMaternal obesity during pregnancy and gestational diabetes mellitus (GDM) are both associated with of several postnatal diseases in the offspring, including obesity, early onset hypertension, diabetes mellitus, and reproductive alterations. Metformin is an oral drug that is being evaluated to treat GDM, obesity-associated insulin resistance, and polycystic ovary syndrome (PCOS) during pregnancy. The beneficial effects of metformin on glycemia and pregnancy outcomes place it as a good alternative for its use during pregnancy. In this line of thought, improving the metabolic status of the pregnant mother by using metformin should avoid the consequences of insulin resistance on the offspring's fetal and postnatal development. However, some human and animal studies have shown that metformin during pregnancy could amplify these alterations and be associated with excessive postnatal weight gain and obesity. In this minireview, we discuss not only the clinical and experimental evidence that supports the benefits of using metformin during pregnancy but also the evidence showing a possible negative impact of this drug on the offspring's development.en_ES
dc.facultadFacultad de Cienciasen_ES
dc.identifier.doi10.3389/fphar.2020.00653
dc.identifier.urihttp://repositoriobibliotecas.uv.cl/handle/uvscl/3794
dc.language.isoenen_ES
dc.sourceFrontiers in Pharmacologyen_ES
dc.subjectMETFORMINen_ES
dc.subjectPREGNANCYen_ES
dc.subjectPOLYCYSTIC OVARY SYNDROMEen_ES
dc.subjectDIABETES MELLITUSen_ES
dc.subjectPOSTNATALen_ES
dc.subjectBODYWEIGHTen_ES
dc.titleMetformin during Pregnancy: Effects on Offspring Development and Metabolic Functionen_ES
dc.typeArticuloen_ES
uv.catalogadorRCR DIBRAen_ES
uv.departamentoInstituto de Fisiologiaen_ES

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
2020 Sotomayor-Zarate R. Frontiers in Pharmacology.pdf
Tamaño:
320.12 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
384 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos investigadores UV